NewAmsterdam Pharma Co N.V. (NAMS) research
NewAmsterdam Pharma Co N.V.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $23.32
- As of
NewAmsterdam Pharma Co N.V. (NAMS): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-21.
As of . Source: SEC EDGAR filings for NAMS. Method and limitations.
Share the NAMS intelligence card
See NAMS live in the terminal
Track NAMS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live NAMS terminal, freeActive signals for NAMS
- highCONSENSUS_BUY
5 tracked funds increased NAMS this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased NAMS this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +828% to NAMS (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +65% to NAMS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +989% to NAMS (2026Q2)
FREE, NO ACCOUNT
Every signal on NAMS, as it fires
You are seeing 5 of 31 signals recorded on NAMS since 2026-06-05.
The five above landed across 2 days. The other 26 were recorded on 4 other days. 21 of the 31 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NAMS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP N62509109 · 2026Q2 | $142.5M | 0.41% | , |
| CITADEL ADVISORS LLCCUSIP N62509109 · 2026Q2 | $21.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP N62509109 · 2026Q2 | $17M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP N62509109 · 2026Q2 | $5.7M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP N62509109 · 2026Q2 | $4.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP N62509109 · 2026Q2 | $407K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NAMS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NAMS against its peers
NAMS's operating margin of -1002.9% ranks in the 44th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | NAMS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 22.5M USD | 77.4M USD | 38 | 16 |
| Operating margin | -1002.9% | -426.5% | 44 | 16 |
| Net margin | -905.7% | -399.2% | 44 | 16 |
| Return on equity | -29.8% | -48.3% | 63 | 22 |
Peers (23): NRIX, PGEN, PHVS, IRON, MLYS, IMNM, ATAI, ZLAB, VRDN, VERA, BEAM, ARQT, MBX, QURE, CLDX, SLS, AUPH, BCRX, SRPT, PVLA, RCUS, VCYT, ZBIO. Left out: ZLDPF (no annual filing), BRVE (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NAMS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NAMS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NAMSand get the insider, 13F, options, and confluence read in one view.